Targeted cancer therapies can suppress T cell immune responses, study finds
March 23, 2016Research and Development T cell, anti-cancer drugs, immunosuppresive, superagonist, wistar institute
Researchers at the Wistar Institute have developed a new method whereby targeted cancer therapies can provide appropriate therapeutics without supressing …
Celyad teams-up with Institut Curie to advance its immuno-oncology program
March 22, 2016Manufacturing and Production, Research and Development Cancer Immunotherapy, Celyad, Institut Curie, cellular immunotherapies
Celyad (Nasdaq: CYAD) on Tuesday said it has partnered with Institut Curie to develop its NKR-T pipeline in cellular immunotherapies …
Eisai withdraws application for neurodegenerative-disease drug in Japan
March 22, 2016Manufacturing and Production, Research and Development Eisai, mecobalamin, neurodegenerative disease
Pharma major Eisai (TYO: 4523) on Tuesday said the Japanese regulators have stalled the approval of its drug to treat …
BioMarin reports mixed Phase III results for genetic disorder trial-drug Pegvaliase
March 22, 2016Manufacturing and Production, Research and Development
Biotech firm BioMarin Pharmaceutical (Nasdaq: BMRN) reported mixed results for its trial drug to treat genetic disorder phenylketonuria. Trial drug, …
Darzalex to be trialled in combination with atezolizumab in multiple myeloma and solid tumours
March 22, 2016Research and Development Genentech, Genmab, Janssen, Roche, atezolizumab, clnical trials, multiple myeloma, phase ib, solid tumours, tumour
Phase Ib clinical studies are set to begin, which will evaluate Darzalex (daratumumab) in combination with atezolizumab in a solid …
Raptor’s Procysbi gets Priority Review from Health Canada
March 22, 2016Manufacturing and Production, Research and Development Canada, Health Canada, Procysbi, Raptor Pharmaceutical, genetic condition
Raptor Pharmaceutical (Nasdaq: RPTP) said Canadian regulators have accepted a priority review for its drug to treat a rare genetic …
23andMe’s apps to aid genetic research for Apple’s ResearchKit
March 22, 2016Manufacturing and Production, Research and Development 23andME, Apple, genetics, research
Privately-held 23andMe has announced a new module for Apple’s (Nasdaq: AAPL) open source ResearchKit software framework that allows scientists to …
Sosei appoints Peter Bains as COO and CEO-elect
March 22, 2016Research and Development
Japan’s Sosei Group has announced the appointment of Syngene chief executive Peter Bains as representative executive officer and chief operating …
FDA bans clinical trial co-ordinator who faked patient samples and stole funds
March 22, 2016Manufacturing and Production, Medical Communications FDA, HIV, clinical trials, faked, forgery, mcquerry, prison
The US Food and Drug Administration has permanently banned a clinical trial co-ordinator who was found to have falsified patient …
Albumedix technology extends dosing interval in Behring haemophilia B drug
March 22, 2016Manufacturing and Production, Research and Development Albumedix, GSK, Idelvion, Novozymes, VELTIS, haemophilia B
Novozymes subsidiary Albumedix has scored another big pharma tie-up for its albumin-based half-life extension technology VELTIS, which this time is …
FDA approves new anthrax treatment
March 22, 2016Manufacturing and Production, Research and Development Antibacterial, FDA, US, anthim, anthrax, defense, inhalational
The US Food and Drug Administration (FDA) has approved Anthim (obiltoxaximab) to treat inhalational anthrax in combination with appropriate antibacterial …
Takeda presents long-term Entyvio data in CD and UC
March 21, 2016Manufacturing and Production, Research and Development Crohn's, Crohn's and Colitis, Entyvio, Takeda, ulcerative colitis
Japan’s Takeda has presented interim findings from the GEMINI Long-Term Safety (LTS) study of ulcerative colitis drug Entyvio (vedolizumab) at …
ThromboGenics signs €1m licensing deal with Galapagos for diabetic eye disease treatment
March 21, 2016Manufacturing and Production, Research and Development, Sales and Marketing
ThromboGenics NV (Euronext Brussels: THR) on Monday said it has signed a €1 million license deal with Galapagos NV (Nasdaq: …
European Medicines Agency elects Christa Wirthumer-Hoche as new chair of management board
March 21, 2016Medical Communications, Research and Development Christa Wirthumer-Hoche, EMA, European Medicines Agency, chair, chairperson, wirthumer-hoche
Christa Wirthumer-Hoche has been elected chair of the management board of the European Medicine’s Agency. She has served as vice …
Leo Pharma gets EU scientific approval for its psoriasis drug Enstilar
March 21, 2016Business Services, Research and Development, Sales and Marketing EU, Enstilar, LEO Pharma, psoriasis vulgaris
Leo Pharma on Monday said its drug to treat inflammatory skin condition has received scientific approval in the European Union. …
Valeant CEO Pearson to leave company
March 21, 2016Michael Pearson, Valeant
Valeant (NYSE:VRX) has announced that it has begun the search for a new CEO, confirming that Michael Pearson is to …
AstraZeneca buys rights to Orexo respiratory programme
March 21, 2016Sales and Marketing AstraZeneca, COPD, asthma, orexo
AstraZeneca has bought the rights to a respiratory programme from Sweden’s Orexo for $5 million. The deal centres on the …
Novartis’s heart failure drug given final recommendation by NICE
March 21, 2016Manufacturing and Production, Research and Development Entresto, NICE, Novartis, approval, draft, guidance, heart failure, heart failure drug
The National Institute for Health and Care Excellence (NICE) has issued its final guidance on Entresto (sacubritil/valsartan), a heart failure …
NICE approves Janssen’s Zytiga for prostate cancer before chemo
March 21, 2016Sales and Marketing Janssen, NICE, Zytiga, prostate cancer
The National Institute for Health and Care Excellence (NICE) has recommended the use of Janssen’s Zytiga (abiraterone acetate) to treat …
TREND: Smallcap biotechs win in stock markets on positive drug trials
March 21, 2016Research and Development, Sales and Marketing
Troubled Canadian drug firm Valeant Pharma (NYSE: VRX) saw its share price halved in a single day after the company …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
